NovoCure Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure or view top-rated stocks.

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NovoCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for NovoCure.

NovoCure Limited (NASDAQ:NVCR) posted its earnings results on Thursday, April, 29th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.06. The medical equipment provider earned $134.70 million during the quarter, compared to analysts' expectations of $136.54 million. NovoCure had a net margin of 2.22% and a trailing twelve-month return on equity of 3.30%.
View NovoCure's earnings history.

NovoCure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 232.9% and is now trading at $224.29.
View which stocks have been most impacted by COVID-19.

9 brokerages have issued 12-month target prices for NovoCure's stock. Their forecasts range from $142.00 to $250.00. On average, they expect NovoCure's share price to reach $195.71 in the next twelve months. This suggests that the stock has a possible downside of 12.7%.
View analysts' price targets for NovoCure or view top-rated stocks among Wall Street analysts.

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Some companies that are related to NovoCure include Becton, Dickinson and (BDX), Boston Scientific (BSX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), Fresenius SE & Co. KGaA (FSNUY), Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Nevro (NVRO) and Tandem Diabetes Care (TNDM).
View all of NVCR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital International Investors (8.82%), Baillie Gifford & Co. (8.57%), BlackRock Inc. (6.21%), Credit Suisse AG (1.58%), Morgan Stanley (1.19%) and Price T Rowe Associates Inc. MD (1.19%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Franklin Resources Inc., Phoenix Holdings Ltd., Schroder Investment Management Group, Citigroup Inc., C WorldWide Group Holding A S, Bank of New York Mellon Corp, and Montanaro Asset Management Ltd. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure or view top insider-selling stocks.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, BlackRock Inc., Baillie Gifford & Co., Credit Suisse AG, Renaissance Technologies LLC, Victory Capital Management Inc., Geller Advisors LLC, and UBS Asset Management Americas Inc..
View insider buying and selling activity for NovoCure or or view top insider-buying stocks.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCR stock can currently be purchased for approximately $224.29.

NovoCure has a market capitalization of $23.19 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or $0.18 on an earnings per share basis.

NovoCure employs 1,023 workers across the globe.

The official website for NovoCure is www.novocure.com.

NovoCure is headquartered at NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF.

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]